Finally, although Okina et al. also stated that inhibition of REV-7 function might become a therapeutic approach for patients diagnosed with diffuse large B-cell lymphoma who are resistant to rituximab-combined chemotherapy, they did not perform any experiments in order to confirm their hypothesis [16]. This evidence concerns the gene MAD2L2 and diffuse large B-cell lymphoma.